Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake

BACKGROUND: The therapeutic use of [(131)I]meta-iodobenzylguanidine ([(131)I]MIBG) is often accompanied by hematological toxicity, mainly consisting of persistent and severe thrombocytopenia. While MIBG accumulates in neuroblastoma cells via selective uptake by the norepinephrine transporter (NET),...

Descripción completa

Detalles Bibliográficos
Autores principales: Blom, Thomas, Meinsma, Rutger, Rutgers, Marja, Buitenhuis, Corine, Dekken-Van den Burg, Marieke, van Kuilenburg, André B. P., Tytgat, Godelieve A. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343696/
https://www.ncbi.nlm.nih.gov/pubmed/32642907
http://dx.doi.org/10.1186/s13550-020-00662-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343696/
https://www.ncbi.nlm.nih.gov/pubmed/32642907
http://dx.doi.org/10.1186/s13550-020-00662-w

Ejemplares similares